Skip to content

Early treatment of glucose toxicity with sitagliptin prevent progression of arteriosclerosis in cardiovascular disease patients

Early treatment of glucose toxicity with sitagliptin prevent progression of arteriosclerosis in cardiovascular disease patients - SPARC study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006432
Enrollment
100
Registered
2011-09-29
Start date
2011-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

more than 50% coronary artery stenosis with diabetes, including impaired glucose tolerance

Interventions

Sitagliptin is initiated with 50mg/time, 1 times/day, and increased to 100mg/time after examining tolerability if there is no enough therapeutic effect. However, the dosage shall be determined by the

Sponsors

Cardiovascular Center,Anjo Kosei Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who were found at catheterization test to have more than 50 % of stenosis, diagnosed with diabetic (including IGT) at 75g oral glucose tolerance test : 140mg/dl or more, HbA1c : less than 6.5%) are assigned to groups with or without Sitagliptin for comparison. Subjects who are hyperlipidemic or who require administration of statin.

Exclusion criteria

Exclusion criteria: Any subject who applies to the article below shall be excluded. 1) Patients on oral antidiabetic or insulin preparation 2) Patients with a history of ileus or undergone laparotomy 3) Patients with severe liver dysfunction or renal dysfunction 4) Patients with serious case of ketosis or diabetical coma, or precoma 5) Patients with severe infection disease, or in the perioperative period, or with extreme trauma 6)Patient who caused myocardial infarction within the past six months 7) Patients with a history of sensitivity to Sitagliptin 8) Pregnant or possibly pregnant women 9) Patients judged by the investigator/subinvestigator to be ineligible for some other reason

Design outcomes

Primary

MeasureTime frame
incidence of cardiovascular events: new onset myocardial infarction, worsening anginal status and/or angiographic restenosis Carotid intima-medial thickness(IMT)

Secondary

MeasureTime frame
1-1)Ultrasonic echo cardiography(IVS; Interventricular Septal Thickness, EF; Ejection Fraction, E/A, LVDd; Left Ventricular Diastolic dimension) 2-1)HbA1c 2-2)IRI 2-3)blood glucose levels 2-4)HOMA-R,HOMA-beta 3)Plasma lipid profile 4)BNP

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026